CommercialPrior AuthHigh impact
Imetelstat (Rytelo) (CPB 1063, reviewed 2026-06-12)
Aetna·Hematology, Oncology, Internal Medicine·Medical Policy
Effective date
Sep 23, 2024
We identified it
Aug 15, 2026
Summary
Aetna has established new coverage criteria for imetelstat (Rytelo) for lower-risk myelodysplastic syndromes with transfusion-dependent anemia. The policy requires precertification for all commercial plans and specifies strict patient criteria including prior ESA or luspatercept failure and transfusion burden of ≥4 units per 8 weeks. This is a NEW drug approval effective September 23, 2024, requiring immediate workflow updates for precertification processes.
Action Required
By September 23, 2024: Billing team must implement mandatory precertification process for imetelstat (Rytelo) treatment. Update billing software to flag ALL claims for this medication as requiring prior authorization before submission. Designate staff to contact Aetna precertification line (866) 752-7021 or fax (888) 267-3277 for all Rytelo requests. Providers must include Statement of Medical Necessity (SMN) documentation demonstrating: (1) patient has lower-risk MDS (IPSS-R very low, low, or intermediate), (2) transfusion dependence ≥4 RBC units per 8 weeks, and (3) prior ESA ineligibility/failure OR luspatercept failure. Update encounter templates to require documentation of ESA/luspatercept treatment history and transfusion record. Establish tracking system for continuation therapy approvals requiring documentation of maintained transfusion reduction and acceptable toxicity profile. Claims submitted without precertification will be denied. Front desk staff should notify patients that Rytelo requires insurance approval before treatment initiation.